Document is current

Article History

Accepted: 3 April 2023

First Online: 17 May 2023

Declarations

:

: No funding has been received for the preparation of this manuscript.

: Egídio Freitas has no conflicts of interest to declare. Emma Guttman-Yassky declares the following conflicts of interest: AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, Boehringer-Ingelheim, Cara Therapeutics, Celgene, Concert, DBV, Dermira, Dermavant, DS Biopharma, Eli Lilly, EMD Serono, Escalier, Galderma, Glenmark, Innovaderm, Janssen Pharmaceuticals, Kiniksa, Kyowa Kirin, LEO Pharma, Mitsubishi Tanabe, Novan, Pfizer, Ralexar, RAPT Therapeutics, Regeneron, Sanofi, Sienna Biopharma, UCB, and Union Therapeutics. Tiago Torres declares the following conflicts of interest: AbbVie, Amgen, Almirall, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Biocad, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme and Sandoz.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Egídio Freitas, Emma Guttman-Yassky, and Tiago Torres had the idea for the article, performed the literature search and data analysis, and drafted and critically revised the work. All authors read and approved the final manuscript.

Free to read: This content has been made available to all.